Treatment of Clostridioides difficile Infection and Non-compliance with Treatment Guidelines in Adults in 10 US Geographical Locations, 2013–2015
Infectious Diseases Society of America/Society for Healthcare Epidemiology of America (IDSA/SHEA) guidelines describe recommended therapy for Clostridioides difficile infection (CDI).
To describe CDI treatment and, among those with severe CDI, determine predictors of adherence to the 2010 IDSA/SHEA treatment guidelines.
We analyzed 2013–2015 CDI treatment data collected through the Centers for Disease Control and Prevention’s Emerging Infections Program. Generalized linear mixed models were used to identify predictors of guideline-adherent therapy.
A CDI case was defined as a positive stool specimen in a person aged ≥ 18 years without a positive test in the prior 8 weeks; severe CDI cases were defined as having a white blood cell count ≥ 15,000 cells/μl.
Prescribing and predictors of guideline-adherent CDI therapy for severe disease.
Of 18,243 cases, 14,257 (78%) were treated with metronidazole, 7683 (42%) with vancomycin, and 313 (2%) with fidaxomicin. The median duration of therapy was 14 (interquartile range, 11–15) days. Severe CDI was identified in 3250 (18%) cases; of 3121 with treatment data available, 1480 (47%) were prescribed guideline-adherent therapy. Among severe CDI cases, hospital admission (adjusted odds ratio [aOR] 2.48; 95% confidence interval [CI] 1.90, 3.24), age ≥ 65 years (aOR 1.37; 95% CI 1.10, 1.71), Charlson comorbidity index ≥ 3 (aOR 1.27; 95% CI 1.04, 1.55), immunosuppressive therapy (aOR 1.21; 95% CI 1.02, 1.42), and inflammatory bowel disease (aOR 1.56; 95% CI 1.13, 2.17) were associated with being prescribed guideline-adherent therapy.
Provider adherence to the 2010 treatment guidelines for severe CDI was low. Although the updated 2017 CDI guidelines, which expand the use of oral vancomycin for all CDI, might improve adherence by removing the need to apply severity criteria, other efforts to improve adherence are likely needed, including educating providers and addressing barriers to prescribing guideline-adherent therapy, particularly in outpatient settings.
KEY WORDSinfectious disease decision-making epidemiology Clostridioides difficile
We would like to acknowledge Lucy Fike for her assistance in data analysis and Deborah Nelson, Rebecca Tsay, Olivia Almendares, Zirka Smith, Catherine Espinosa, Michelle Wiles, and Wendy Bamberg for their assistance in collecting and managing EIP data.
Conflict of Interest
D.N.G. is a member of the Scientific Advisory Boards of Merck, Rebiotix, Actelion, DaVolterra, and Summit; is a consultant for Pfizer, MGB Pharma, and Sanofi Pasteur; holds a research grant from Seres Therapeutics; and holds patents and technology for the prevention of CDI. G.K.D. serves on the Drug Safety Monitoring Board for a C. difficile treatment study by Seres. All other authors have no known conflicts of interest.
The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the US Centers for Disease Control and Prevention.
Compliance with Ethical Standards
This surveillance activity underwent ethical review by CDC and all EIP sites and either was deemed non-research or received an institutional review board approval with a waiver of informed consent.
- 1.Magill SS, O'Leary E, Janelle SJ, et al. Changes in prevalance of health care-associated infections in U.S. Hospitals. The New England journal of medicine. 2018 Nov 1;379(18):1732-44.Google Scholar
- 3.Hensgens MP, Goorhuis A, Dekkers OM, van Benthem BH, Kuijper EJ. All-cause and disease-specific mortality in hospitalized patients with Clostridium difficile infection: a multicenter cohort study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2013 Apr;56(8):1108-16.CrossRefGoogle Scholar
- 7.Forster AJ, Taljaard M, Oake N, Wilson K, Roth V, van Walraven C. The effect of hospital-acquired infection with Clostridium difficile on length of stay in hospital. CMAJ : Canadian Medical Association journal = journal de l’Association medicale canadienne. 2012 Jan 10;184(1):37-42.CrossRefGoogle Scholar
- 8.Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infection control and hospital epidemiology. 2010 May;31(5):431-55.CrossRefGoogle Scholar
- 9.McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clinical Infectious Diseases. 2018;66(7):e1-e48.CrossRefGoogle Scholar
- 10.Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2007 Aug 1;45(3):302-7.CrossRefGoogle Scholar
- 11.Johnson S, Louie TJ, Gerding DN, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2014 Aug 1;59(3):345-54.CrossRefGoogle Scholar
- 17.Emerging Infections Program. [cited 2019 July 23]; Available from: https://www.cdc.gov/ncezid/dpei/eip/index.html.
- 18.Clostridium difficile Infection (CDI) Tracking. [cited 2019 July 23]; Available from: https://www.cdc.gov/hai/eip/clostridium-difficile.html.
- 20.Siegfried JD, Yanina; Flagiello, Thomas, Scipione, Marco R.; Phillips, Michael; Papadopoulos, John; Chen, Donald; Safdar, Amar Initial Therapy for Mild to Moderate Clostridium difficile Infection: Exploring the Role of Oral Metronidazole Versus Vancomycin in 168 Hospitalized Patients. Infectious Diseases in Clinical Practice. 2016;24(4):210-6.Google Scholar
- 22.Pattani R, Palda VA, Hwang SW, Shah PS. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile infection among hospitalized patients: systematic review and meta-analysis. Open medicine : a peer-reviewed, independent, open-access journal. 2013;7(2):e56-67.Google Scholar
- 23.Giancola SE, Williams RJ, 2nd, Gentry CA. Evaluation of fidaxomicin usage patterns and outcomes for Clostridium difficile infection across the United States Veterans Health Administration. Journal of clinical pharmacy and therapeutics. 2018 Jan 21.Google Scholar
- 24.Fidaxomicin, DIFICID - FDA. [cited 2019 July 23]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201699s000lbl.pdf.
- 25.Cruz MP. Fidaxomicin (Dificid), a Novel Oral Macrocyclic Antibacterial Agent For the Treatment of Clostridium difficile-Associated Diarrhea in Adults. P & T : a peer-reviewed journal for formulary management. 2012 May;37(5):278-81.Google Scholar